

Supplement Table 1.

Exon 19 deletion	Osimertinib Line	Age	Sex	Smoking History	Disease Control	PFS (months)	TTD (months)	OS (months)
E746_T751>A	1	69	M	+	+	19.6	27.3→	27.3→
	1	53	M	-	+	17.3	19.4	21.7
	2 (T790M+)	65	M	-	+	34.9	46.6	49.4
	2 (T790M+)	67	F	-	+	14.0	29.6	41.7
	2 (T790M+)	79	M	+	+	9.8	10.6	28.2
L747_S752del	1	53	F	-	+	26.6→	29.6→	29.6→
	1	50	F	-	+	4.8	6.0	12.1→
	1	62	F	-	+	33.8→	34.2→	34.2→
	2 (T790M+)	70	F	+	+	13.3	22.0	26.6
	3 (T790M+)	65	F	-	+	3.2	16.6	22.1
E746_P753>VS	1	47	M	+	+	11.2	15.4→	15.4→
	1	45	F	-	-	2.7	2.8	2.9
	1	43	F	-	+	19.2	25.5→	25.5→
	3 (T790M+)	65	M	-	+	45.1	60.3→	60.5→
E746_T751>V	1	59	F	-	+	16.4	16.6	22.1
	1	71	F	-	+	23.1→	24.3→	24.3→
E746_T751>VP	1	53	F	-	+	26.6→	29.6→	29.6→
A750_I759>PT	1	66	F	-	+	8.3	8.8→	8.8→
E746_P753>IS	1	73	F	-	+	13.8→	16.5→	16.5→
L747_S752>QH	1	56	F	+	+	12.4→	16.0→	16.0→
S752_I759del	1	60	M	-	+	30.0	32.5	32.8→
T751_I759>S	1	72	F	-	-	2.6	2.6	10.3
L747_A750del	3 (T790M+)	72	F	+	+	8.0	2.8	10.2→
L747_S752>Q	2 (T790M+)	65	F	-	+	52.5→	53.6→	53.6→

Supplementary Table 1. Descriptive analysis of patient characteristics and outcomes for those with tumors harboring uncommon exon 19 deletions treated with osimertinib. Each variant represented $\leq 2.5\%$ of the study cohort. Patients with + for “Smoking History” are those with either a prior or current smoking history. PFS=Progression free survival; OS= Overall survival; denotes patients who have not yet experienced an event for a time to event endpoint.